# Davidson_2023_Tryptophan and Substance Abuse Mechanisms and Impact.

Review
Tryptophan and Substance Abuse: Mechanisms and Impact

Majid Davidson 1,2
and Vasso Apostolopoulos 1,6,*

, Niloufar Rashidi 1, Md Kamal Hossain 1, Ali Raza 3,4, Kulmira Nurgali 1,2,5,*

1

Institute for Health and Sport, Victoria University, Melbourne, VIC 3021, Australia

2 Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS),

Melbourne, VIC 3021, Australia
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3353, Australia
Federation University, Ballarat, VIC 3353, Australia

3

4

5 Department of Medicine Western Health, Faculty of Medicine, Dentistry and Health Sciences,

6

University of Melbourne, Melbourne, VIC 3021, Australia
Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS),
Melbourne, VIC 3021, Australia

* Correspondence: kulmira.nurgali@vu.edu.au (K.N.); vasso.apostolopoulos@vu.edu.au (V.A.)

Abstract: Addiction, the continuous misuse of addictive material, causes long-term dysfunction
in the neurological system. It substantially affects the control strength of reward, memory, and
motivation. Addictive substances (alcohol, marijuana, caffeine, heroin, methamphetamine (METH),
and nicotine) are highly active central nervous stimulants. Addiction leads to severe health issues,
including cardiovascular diseases, serious infections, and pulmonary/dental diseases. Drug depen-
dence may result in unfavorable cognitive impairments that can continue during abstinence and
negatively inﬂuence recovery performance. Although addiction is a critical global health challenge
with numerous consequences and complications, currently, there are no efﬁcient options for treating
drug addiction, particularly METH. Currently, novel treatment approaches such as psychological
contingency management, cognitive behavioral therapy, and motivational enhancement strategies are
of great interest. Herein, we evaluate the devastating impacts of different addictive substances/drugs
on users(cid:48) mental health and the role of tryptophan in alleviating unfavorable side effects. The trypto-
phan metabolites in the mammalian brain and their potential to treat compulsive abuse of addictive
substances are investigated by assessing the functional effects of addictive substances on tryptophan.
Future perspectives on developing promising modalities to treat addiction and the role of tryptophan
and its metabolites to alleviate drug dependency are discussed.

Keywords: tryptophan; kynurenine; serotonin; addiction; mental health; methamphetamine

1. Introduction

Drug addiction is identiﬁed as a compulsive relapsing disorder that has devastating
effects on the brain and behavior of users and results in a disability to control the drug-
seeking tendency and use, notwithstanding unfavorable consequences [1]. DA is initiated
via experimental utilization of a recreational drug in society or exposure to a prescribed
medicine from a friend [2,3]. Substances including methamphetamine (METH), alcohol,
marijuana, heroin, and nicotine are the most commonly used addictive drugs that may
have disparate detrimental side effects on users. Numerous short-term and long-term side
effects such as insomnia, drowsiness, increased blood pressure, uncontrolled movement,
and rapid heart rate are the dire and unfavorable consequences of disparate addictive drug
abuse [4,5].

In recent decades, alcohol addiction has been a global crisis that accounts for almost
5% of the disease burden [6]. Based on the statistics, alcohol is the most prevalently abused
substance in the United States and is responsible for 3.5% of annual deaths due to its
detrimental and deleterious effects, such as liver cirrhosis and neurotoxicity [7]. Therefore,

Citation: Davidson, M.; Rashidi, N.;

Hossain, M.K.; Raza, A.; Nurgali, K.;

Apostolopoulos, V. Tryptophan and

Substance Abuse: Mechanisms and

Impact. Int. J. Mol. Sci. 2023, 24, 2737.

https://doi.org/10.3390/ijms24032737

Academic Editor: Marco Fiore

Received: 4 January 2023

Revised: 22 January 2023

Accepted: 28 January 2023

Published: 1 February 2023

Copyright: © 2023 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under

the terms and

conditions of the Creative Commons

Attribution (CC BY) license (https://

creativecommons.org/licenses/by/

4.0/).

Int. J. Mol. Sci. 2023, 24, 2737. https://doi.org/10.3390/ijms24032737

https://www.mdpi.com/journal/ijms

 International Journal of Molecular SciencesInt. J. Mol. Sci. 2023, 24, 2737

2 of 17

developing cost-effective and promising drugs to treat alcohol addiction is crucial, as only a
small proportion of patients can achieve effective remission. Marijuana (whose street names
include dope, pot, grass, weed, and hashish) manifests as an addictive drug extracted from
the cannabis plant. Tetrahydrocannabinol is the active ingredient in marijuana, which is
the main reason for its potential for dependency. This addictive substance can signiﬁcantly
change perception due to its psychoactive characteristics. Depending on the mode of
administration, marijuana can produce various neuropsychological disorders such as
hallucinations, abnormal happiness, and difﬁculty concentrating [8]. Heroin, another
commonly used addictive substance produced from morphine [9,10], is highly abused
among people from various social cultures. Heroin targets the brain and receptors on cells,
which increases the heart rate and causes breathing and sleeping issues [11,12]. In addition,
dry mouth, drowsiness, constipation, and depression are common side effects [13].

The World Health Organization predicts that almost one-third of the global adult
population smokes tobacco, accounting for many smoking-related deaths [14,15]. Nicotine
(one of the foremost effective ingredients in tobacco) is a naturally manufactured alkaloid
used as an anxiolytic stimulant [16]. Similar to other psychostimulant agents, nicotine
increases extracellular dopamine concentrations in the nucleus accumbens, which can cause
neuropsychological/behavioral alterations in users [17]. Table 1 provides information
regarding common addictive substances.

Table 1. Some of the common addictive substances, mechanisms of action, and side effects.

Mechanism of
Action

Chemical
Structure

Mode of
Administration

Side Effects

Ref.

Drug

Alcohol

Caffeine

Cocaine

Promotion of
inhibitory
neurotransmission

Release of
dopamine,
serotonin, and
noradrenaline

Potentiation of
dopamine and
norepinephrine

Heroin

Stimulation of
opioid receptor

Marijuana

Stimulation of
cannabinoid
receptor type 1 and
cannabinoid
receptor type 2

Oral

Oral

Injection
Inhalation

Injection
Inhalation

Oral
Smoke

Liver cirrhosis
Neurotoxicity
Drowsiness
Loss of consciousness
Gaps in memory
Increased vigilance and
metabolic activity
Insomnia
Nervousness
Restlessness
Nausea

Euphoria
Increased concentration
Pupillary dilation

Analgesia
Depression
Pupillary constriction
Pneumonia
Increased heart rate
Difﬁculty sleeping
Difﬁculty breathing
Dry mouth
Tachycardia
High blood pressure
Decrease in saccadic
accuracy
Difﬁculty concentrating
Hallucinations
Abnormal happiness
Depression

[6,18,19]

[20–23]

[24,25]

[10,26,27]

[28–30]

Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 2 of 18   substance in the United States and is responsible for 3.5% of annual deaths due to its det‐rimental and deleterious effects, such as liver cirrhosis and neurotoxicity [7]. Therefore, developing cost‐effective and promising drugs to treat alcohol addiction is crucial, as only a small proportion of patients can achieve effective remission. Marijuana (whose street names include dope, pot, grass, weed, and hashish) manifests as an addictive drug ex‐tracted from the cannabis plant. Tetrahydrocannabinol is the active ingredient in mariju‐ana, which is the main reason for its potential for dependency. This addictive substance can significantly change perception due to its psychoactive characteristics. Depending on the mode of administration, marijuana can produce various neuropsychological disorders such as hallucinations, abnormal happiness, and difficulty concentrating [8]. Heroin, an‐other commonly used addictive substance produced from morphine [9,10], is highly abused among people from various social  cultures. Heroin targets the brain and receptors on cells, which increases the heart rate and causes breathing and sleeping issues [11,12]. In addition, dry mouth, drowsiness, constipation, and depression are common side effects [13]. The World Health Organization predicts that almost one‐third of the global adult population smokes tobacco, accounting for many smoking‐related deaths [14,15]. Nico‐tine (one of the foremost effective ingredients in tobacco) is a naturally manufactured al‐kaloid used as an anxiolytic stimulant [16]. Similar to other psychostimulant agents, nic‐otine increases extracellular dopamine concentrations in the nucleus accumbens, which can cause neuropsychological/behavioral alterations in users [17]. Table 1 provides infor‐mation regarding common addictive substances. Table 1. Some of the common addictive substances, mechanisms of action, and side effects. Drug Mechanism of Action Chemical Structure Mode of Ad‐ministration Side Effects Ref. Alcohol Promotion of inhibi‐tory neurotransmis‐sion  Oral Liver cirrhosis Neurotoxicity Drowsiness Loss of consciousness Gaps in memory [6,18,19] Caffeine Release of dopamine, serotonin, and nora‐drenaline  Oral Increased vigilance and meta‐bolic activity Insomnia Nervousness Restlessness Nausea [20–23] Cocaine Potentiation of dopa‐mine and norepineph‐rine  Injection Inhalation Euphoria Increased concentration Pupillary dilation [24,25] Heroin Stimulation of opioid receptor  Injection Inhalation Analgesia Depression Pupillary constriction Pneumonia Increased heart rate Difficulty sleeping Difficulty breathing Dry mouth [10,26,27] Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 2 of 18   substance in the United States and is responsible for 3.5% of annual deaths due to its det‐rimental and deleterious effects, such as liver cirrhosis and neurotoxicity [7]. Therefore, developing cost‐effective and promising drugs to treat alcohol addiction is crucial, as only a small proportion of patients can achieve effective remission. Marijuana (whose street names include dope, pot, grass, weed, and hashish) manifests as an addictive drug ex‐tracted from the cannabis plant. Tetrahydrocannabinol is the active ingredient in mariju‐ana, which is the main reason for its potential for dependency. This addictive substance can significantly change perception due to its psychoactive characteristics. Depending on the mode of administration, marijuana can produce various neuropsychological disorders such as hallucinations, abnormal happiness, and difficulty concentrating [8]. Heroin, an‐other commonly used addictive substance produced from morphine [9,10], is highly abused among people from various social  cultures. Heroin targets the brain and receptors on cells, which increases the heart rate and causes breathing and sleeping issues [11,12]. In addition, dry mouth, drowsiness, constipation, and depression are common side effects [13]. The World Health Organization predicts that almost one‐third of the global adult population smokes tobacco, accounting for many smoking‐related deaths [14,15]. Nico‐tine (one of the foremost effective ingredients in tobacco) is a naturally manufactured al‐kaloid used as an anxiolytic stimulant [16]. Similar to other psychostimulant agents, nic‐otine increases extracellular dopamine concentrations in the nucleus accumbens, which can cause neuropsychological/behavioral alterations in users [17]. Table 1 provides infor‐mation regarding common addictive substances. Table 1. Some of the common addictive substances, mechanisms of action, and side effects. Drug Mechanism of Action Chemical Structure Mode of Ad‐ministration Side Effects Ref. Alcohol Promotion of inhibi‐tory neurotransmis‐sion  Oral Liver cirrhosis Neurotoxicity Drowsiness Loss of consciousness Gaps in memory [6,18,19] Caffeine Release of dopamine, serotonin, and nora‐drenaline  Oral Increased vigilance and meta‐bolic activity Insomnia Nervousness Restlessness Nausea [20–23] Cocaine Potentiation of dopa‐mine and norepineph‐rine  Injection Inhalation Euphoria Increased concentration Pupillary dilation [24,25] Heroin Stimulation of opioid receptor  Injection Inhalation Analgesia Depression Pupillary constriction Pneumonia Increased heart rate Difficulty sleeping Difficulty breathing Dry mouth [10,26,27] Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 2 of 18   substance in the United States and is responsible for 3.5% of annual deaths due to its det‐rimental and deleterious effects, such as liver cirrhosis and neurotoxicity [7]. Therefore, developing cost‐effective and promising drugs to treat alcohol addiction is crucial, as only a small proportion of patients can achieve effective remission. Marijuana (whose street names include dope, pot, grass, weed, and hashish) manifests as an addictive drug ex‐tracted from the cannabis plant. Tetrahydrocannabinol is the active ingredient in mariju‐ana, which is the main reason for its potential for dependency. This addictive substance can significantly change perception due to its psychoactive characteristics. Depending on the mode of administration, marijuana can produce various neuropsychological disorders such as hallucinations, abnormal happiness, and difficulty concentrating [8]. Heroin, an‐other commonly used addictive substance produced from morphine [9,10], is highly abused among people from various social  cultures. Heroin targets the brain and receptors on cells, which increases the heart rate and causes breathing and sleeping issues [11,12]. In addition, dry mouth, drowsiness, constipation, and depression are common side effects [13]. The World Health Organization predicts that almost one‐third of the global adult population smokes tobacco, accounting for many smoking‐related deaths [14,15]. Nico‐tine (one of the foremost effective ingredients in tobacco) is a naturally manufactured al‐kaloid used as an anxiolytic stimulant [16]. Similar to other psychostimulant agents, nic‐otine increases extracellular dopamine concentrations in the nucleus accumbens, which can cause neuropsychological/behavioral alterations in users [17]. Table 1 provides infor‐mation regarding common addictive substances. Table 1. Some of the common addictive substances, mechanisms of action, and side effects. Drug Mechanism of Action Chemical Structure Mode of Ad‐ministration Side Effects Ref. Alcohol Promotion of inhibi‐tory neurotransmis‐sion  Oral Liver cirrhosis Neurotoxicity Drowsiness Loss of consciousness Gaps in memory [6,18,19] Caffeine Release of dopamine, serotonin, and nora‐drenaline  Oral Increased vigilance and meta‐bolic activity Insomnia Nervousness Restlessness Nausea [20–23] Cocaine Potentiation of dopa‐mine and norepineph‐rine  Injection Inhalation Euphoria Increased concentration Pupillary dilation [24,25] Heroin Stimulation of opioid receptor  Injection Inhalation Analgesia Depression Pupillary constriction Pneumonia Increased heart rate Difficulty sleeping Difficulty breathing Dry mouth [10,26,27] Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 2 of 18   substance in the United States and is responsible for 3.5% of annual deaths due to its det‐rimental and deleterious effects, such as liver cirrhosis and neurotoxicity [7]. Therefore, developing cost‐effective and promising drugs to treat alcohol addiction is crucial, as only a small proportion of patients can achieve effective remission. Marijuana (whose street names include dope, pot, grass, weed, and hashish) manifests as an addictive drug ex‐tracted from the cannabis plant. Tetrahydrocannabinol is the active ingredient in mariju‐ana, which is the main reason for its potential for dependency. This addictive substance can significantly change perception due to its psychoactive characteristics. Depending on the mode of administration, marijuana can produce various neuropsychological disorders such as hallucinations, abnormal happiness, and difficulty concentrating [8]. Heroin, an‐other commonly used addictive substance produced from morphine [9,10], is highly abused among people from various social  cultures. Heroin targets the brain and receptors on cells, which increases the heart rate and causes breathing and sleeping issues [11,12]. In addition, dry mouth, drowsiness, constipation, and depression are common side effects [13]. The World Health Organization predicts that almost one‐third of the global adult population smokes tobacco, accounting for many smoking‐related deaths [14,15]. Nico‐tine (one of the foremost effective ingredients in tobacco) is a naturally manufactured al‐kaloid used as an anxiolytic stimulant [16]. Similar to other psychostimulant agents, nic‐otine increases extracellular dopamine concentrations in the nucleus accumbens, which can cause neuropsychological/behavioral alterations in users [17]. Table 1 provides infor‐mation regarding common addictive substances. Table 1. Some of the common addictive substances, mechanisms of action, and side effects. Drug Mechanism of Action Chemical Structure Mode of Ad‐ministration Side Effects Ref. Alcohol Promotion of inhibi‐tory neurotransmis‐sion  Oral Liver cirrhosis Neurotoxicity Drowsiness Loss of consciousness Gaps in memory [6,18,19] Caffeine Release of dopamine, serotonin, and nora‐drenaline  Oral Increased vigilance and meta‐bolic activity Insomnia Nervousness Restlessness Nausea [20–23] Cocaine Potentiation of dopa‐mine and norepineph‐rine  Injection Inhalation Euphoria Increased concentration Pupillary dilation [24,25] Heroin Stimulation of opioid receptor  Injection Inhalation Analgesia Depression Pupillary constriction Pneumonia Increased heart rate Difficulty sleeping Difficulty breathing Dry mouth [10,26,27] Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 3 of 18   Marijuana Stimulation of canna‐binoid receptor type 1 and cannabinoid re‐ceptor type 2  Oral Smoke Tachycardia High blood pressure Decrease in saccadic accuracy Difficulty concentrating Hallucinations Abnormal happiness Depression [28–30] Metham‐phetamine Catecholamine poten‐tiation   Injection Inhalation Oral Intranasal sniff‐ing Depression Euphoria Pupillary dilation Cardiovascular diseases [31–33] Nicotine Nicotinic acetylcho‐line agonist  Oral Smoke Delayed coronary healing Hypertension Tachycardia Smoke‐associated dryness [34–36] Despite the availability of current treatment options, such as behavioral therapy and medication‐assisted treatment, they are often ineffective for addressing the underlying mechanisms of addiction [37,38]. These treatments typically involve behavioral therapies, medications, and support groups, but they do not address the underlying neurobiological mechanisms of addiction. Understanding the mechanisms of addiction and its physiolog‐ical impacts can provide an opportunity for developing a more efficient treatment for this global health issue. Tryptophan is an essential amino acid that plays vital roles in several critical biological processes, including the regulation of mood and behavior [39]. Addic‐tion leads to an imbalance in the levels of tryptophan and its metabolites, which can result in serious health issues [40]. Understanding the connection between tryptophan and ad‐diction may hold potential for developing novel therapeutic approaches for addiction treatment. In this review article, the detrimental effects of addictive substances, specifically METH, on human mental and psychological dependency are evaluated. The role of METH and other addictive substances on mental and psychological dependency in humans is presented, along with a description of tryptophan metabolites in the mammalian brain and their potential as new treatment options for controlling compulsive substance abuse. The functional effects of METH on tryptophan and its disparate metabolites, including serotonin 5‐HT (5‐hydroxytryptophan), melatonin, kynurenine, and reactive oxygen and nitrogen species, as well as the formation and structure of each, are examined. The under‐standing of the connection between tryptophan metabolites and addiction provides a val‐uable opportunity to investigate future perspectives on the development of promising modalities for addiction treatment. 2. General Effects of Addiction on the Body The abuser of disparate types of addictive materials usually suffers from one or more health‐related challenges (Figure 1). Tobacco smoke may increase the risk of cancers, heart failure, brain stroke, lung diseases, and chronic obstructive pulmonary diseases such as emphysema and bronchitis. Smoking also increases the risk of tuberculosis, certain eye diseases, and autoimmune system diseases such as rheumatoid arthritis [41,42]. Int. J. Mol. Sci. 2023, 24, 2737

3 of 17

Table 1. Cont.

Drug

Mechanism of
Action

Chemical
Structure

Methamphetamine

Catecholamine
potentiation

Nicotine

Nicotinic
acetylcholine
agonist

Mode of
Administration

Injection
Inhalation
Oral
Intranasal snifﬁng

Oral
Smoke

Side Effects

Ref.

Depression
Euphoria
Pupillary dilation
Cardiovascular diseases
Delayed coronary healing
Hypertension
Tachycardia
Smoke-associated dryness

[31–33]

[34–36]

Despite the availability of current treatment options, such as behavioral therapy and
medication-assisted treatment, they are often ineffective for addressing the underlying
mechanisms of addiction [37,38]. These treatments typically involve behavioral therapies,
medications, and support groups, but they do not address the underlying neurobiological
mechanisms of addiction. Understanding the mechanisms of addiction and its physiological
impacts can provide an opportunity for developing a more efﬁcient treatment for this global
health issue. Tryptophan is an essential amino acid that plays vital roles in several critical
biological processes, including the regulation of mood and behavior [39]. Addiction leads
to an imbalance in the levels of tryptophan and its metabolites, which can result in serious
health issues [40]. Understanding the connection between tryptophan and addiction may
hold potential for developing novel therapeutic approaches for addiction treatment.

In this review article, the detrimental effects of addictive substances, speciﬁcally
METH, on human mental and psychological dependency are evaluated. The role of METH
and other addictive substances on mental and psychological dependency in humans is
presented, along with a description of tryptophan metabolites in the mammalian brain and
their potential as new treatment options for controlling compulsive substance abuse. The
functional effects of METH on tryptophan and its disparate metabolites, including serotonin
5-HT (5-hydroxytryptophan), melatonin, kynurenine, and reactive oxygen and nitrogen
species, as well as the formation and structure of each, are examined. The understanding
of the connection between tryptophan metabolites and addiction provides a valuable
opportunity to investigate future perspectives on the development of promising modalities
for addiction treatment.

2. General Effects of Addiction on the Body

The abuser of disparate types of addictive materials usually suffers from one or more
health-related challenges (Figure 1). Tobacco smoke may increase the risk of cancers, heart
failure, brain stroke, lung diseases, and chronic obstructive pulmonary diseases such as
emphysema and bronchitis. Smoking also increases the risk of tuberculosis, certain eye
diseases, and autoimmune system diseases such as rheumatoid arthritis [41,42].

Marijuana is known as the most commonly abused addictive drug in the United States,
and its use is expanding substantially in all adult age groups of both sexes. Abusing these
addictive substances can signiﬁcantly enhance the risk of permanent intelligence quotient
(IQ) loss by eight points. Moreover, different studies have corroborated the existence of a
close relationship between marijuana abuse and psychotic disorders such as depression,
anxiety, and suicidal ideation [43,44].

Likewise, the unusual use of alcohol is increasing worldwide and is regarded as
one of the main reasons for chronic liver diseases [45]. Long-term abuse of alcohol may
also increase the risk of chronic diseases such as hypertension, decreased immune system
functioning, digestive problems, and cancer.

Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 3 of 18   Marijuana Stimulation of canna‐binoid receptor type 1 and cannabinoid re‐ceptor type 2  Oral Smoke Tachycardia High blood pressure Decrease in saccadic accuracy Difficulty concentrating Hallucinations Abnormal happiness Depression [28–30] Metham‐phetamine Catecholamine poten‐tiation   Injection Inhalation Oral Intranasal sniff‐ing Depression Euphoria Pupillary dilation Cardiovascular diseases [31–33] Nicotine Nicotinic acetylcho‐line agonist  Oral Smoke Delayed coronary healing Hypertension Tachycardia Smoke‐associated dryness [34–36] Despite the availability of current treatment options, such as behavioral therapy and medication‐assisted treatment, they are often ineffective for addressing the underlying mechanisms of addiction [37,38]. These treatments typically involve behavioral therapies, medications, and support groups, but they do not address the underlying neurobiological mechanisms of addiction. Understanding the mechanisms of addiction and its physiolog‐ical impacts can provide an opportunity for developing a more efficient treatment for this global health issue. Tryptophan is an essential amino acid that plays vital roles in several critical biological processes, including the regulation of mood and behavior [39]. Addic‐tion leads to an imbalance in the levels of tryptophan and its metabolites, which can result in serious health issues [40]. Understanding the connection between tryptophan and ad‐diction may hold potential for developing novel therapeutic approaches for addiction treatment. In this review article, the detrimental effects of addictive substances, specifically METH, on human mental and psychological dependency are evaluated. The role of METH and other addictive substances on mental and psychological dependency in humans is presented, along with a description of tryptophan metabolites in the mammalian brain and their potential as new treatment options for controlling compulsive substance abuse. The functional effects of METH on tryptophan and its disparate metabolites, including serotonin 5‐HT (5‐hydroxytryptophan), melatonin, kynurenine, and reactive oxygen and nitrogen species, as well as the formation and structure of each, are examined. The under‐standing of the connection between tryptophan metabolites and addiction provides a val‐uable opportunity to investigate future perspectives on the development of promising modalities for addiction treatment. 2. General Effects of Addiction on the Body The abuser of disparate types of addictive materials usually suffers from one or more health‐related challenges (Figure 1). Tobacco smoke may increase the risk of cancers, heart failure, brain stroke, lung diseases, and chronic obstructive pulmonary diseases such as emphysema and bronchitis. Smoking also increases the risk of tuberculosis, certain eye diseases, and autoimmune system diseases such as rheumatoid arthritis [41,42]. Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 3 of 18   Marijuana Stimulation of canna‐binoid receptor type 1 and cannabinoid re‐ceptor type 2  Oral Smoke Tachycardia High blood pressure Decrease in saccadic accuracy Difficulty concentrating Hallucinations Abnormal happiness Depression [28–30] Metham‐phetamine Catecholamine poten‐tiation   Injection Inhalation Oral Intranasal sniff‐ing Depression Euphoria Pupillary dilation Cardiovascular diseases [31–33] Nicotine Nicotinic acetylcho‐line agonist  Oral Smoke Delayed coronary healing Hypertension Tachycardia Smoke‐associated dryness [34–36] Despite the availability of current treatment options, such as behavioral therapy and medication‐assisted treatment, they are often ineffective for addressing the underlying mechanisms of addiction [37,38]. These treatments typically involve behavioral therapies, medications, and support groups, but they do not address the underlying neurobiological mechanisms of addiction. Understanding the mechanisms of addiction and its physiolog‐ical impacts can provide an opportunity for developing a more efficient treatment for this global health issue. Tryptophan is an essential amino acid that plays vital roles in several critical biological processes, including the regulation of mood and behavior [39]. Addic‐tion leads to an imbalance in the levels of tryptophan and its metabolites, which can result in serious health issues [40]. Understanding the connection between tryptophan and ad‐diction may hold potential for developing novel therapeutic approaches for addiction treatment. In this review article, the detrimental effects of addictive substances, specifically METH, on human mental and psychological dependency are evaluated. The role of METH and other addictive substances on mental and psychological dependency in humans is presented, along with a description of tryptophan metabolites in the mammalian brain and their potential as new treatment options for controlling compulsive substance abuse. The functional effects of METH on tryptophan and its disparate metabolites, including serotonin 5‐HT (5‐hydroxytryptophan), melatonin, kynurenine, and reactive oxygen and nitrogen species, as well as the formation and structure of each, are examined. The under‐standing of the connection between tryptophan metabolites and addiction provides a val‐uable opportunity to investigate future perspectives on the development of promising modalities for addiction treatment. 2. General Effects of Addiction on the Body The abuser of disparate types of addictive materials usually suffers from one or more health‐related challenges (Figure 1). Tobacco smoke may increase the risk of cancers, heart failure, brain stroke, lung diseases, and chronic obstructive pulmonary diseases such as emphysema and bronchitis. Smoking also increases the risk of tuberculosis, certain eye diseases, and autoimmune system diseases such as rheumatoid arthritis [41,42]. Int. J. Mol. Sci. 2023, 24, 2737

4 of 17

Figure 1. The general short-term and long-term effects of addiction on the body (Figure created with
BioRender.com).

Caffeine, a stimulant found in coffee, tea, energy drinks, and various medications,
acts on the central nervous system by binding to adenosine receptors, leading to increased
alertness and decreased fatigue [46]. While moderate caffeine consumption may provide
some health beneﬁts, excessive caffeine intake can lead to various adverse health outcomes,
such as insomnia, anxiety, high blood pressure, and an increased risk of certain types of
cancer [47]. Long-term heavy caffeine use can also lead to tolerance, withdrawal symptoms,
and difﬁculty reducing or stopping caffeine consumption, ultimately leading to addiction.
Cocaine is one of the most addictive substances, and its abuse may cause the emergence
of many unfavorable and dangerous side effects such as mood disorders, cardiovascular
diseases, weight loss, an increase in the potential risk of human immunodeﬁciency virus
infection, and memory loss [48].

METH is an amine drug that is abused due to its sympathomimetic effects and is taken
via inhalation, ingestion, injection, or smoking [49,50]. METH is a weak lipophilic base that
diffuses across the plasmalemma of the presynaptic neurons and vesicular membranes [51].
METH enters the monoaminergic terminals of neurons due to its structural similarities to
monoamine hormones (serotonin, adrenaline, noradrenaline, dopamine, and melatonin).
It then accumulates in the synaptic vesicles through the action of vesicular monoamine
transporters. It causes an initial outward ﬂow of hormones along with the prevention of
the reuptake of neurotransmitters and their metabolism by enzymes such as monoamine
oxidase [52–54]. Following the initial METH abuse, an increase in the levels of monoamines
occurs [51], leading to an elevation in intra-synaptic levels of monoamine [55]. This increase
results in hallucinations, euphoria, and anorexia [49], as well as risk-taking sexual behaviors,
which raises serious public health and safety concerns [56]. Repetitive and escalating
doses of METH result in decreased monoamine levels due to a reduction in monoamine
transporter binding sites as well as in the activity of synthetic enzymes [57]. The abuse
of addictive drugs such as METH confuses addicts on whether reward-speciﬁc circuits or

Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 5 of 18    Figure 1. The general short‐term and long‐term effects of addiction on the body (Figure created with BioRender.com). 3. Tryptophan and Its Metabolites Tryptophan is an important amino acid that plays a crucial role in various biological processes, including in an infant′s growth, muscle development, enzyme function, and neurotransmitter regulation [64,65]. Tryptophan is a precursor to the metabolites seroto‐nin, melatonin, and kynurenine [66]. Most of the daily intake of tryptophan oxidizes down the kynurenine pathway, whilst the rest degrades via serotonin pathways [67]. Trypto‐phan is metabolized into serotonin and melatonin via the generation of 5‐hydroxytrypto‐phan, which includes human peripheral tryptophan hydroxylase 1 (hpTrpH1) or human neural tryptophan hydroxylase 2 (hnTrpH2), depending on whether metabolism occurs in peripheral entero‐chromatic cells or neural cells of the CNS. 5‐hydroxytryptophan is then metabolized into serotonin and, further down, into melatonin via the action of dif‐ferent enzymes [66,67]. The kynurenine pathway either involves the generation of kynurenic acid (KA) or the formation of 3‐hydroxy‐anthranillic acid, further leading to quinolinic acid (QA). These components, QA and KA, are believed to have noteworthy impacts on CNS neurons. QA possesses the potential for application as a neurotoxin, while KA is a neuroprotectant. 3‐hydroxykynurenine is the third kynurenine metabolite that may create free radicals and aggravate neuronal damage [68]. The kynurenine pathway plays a critical role in regulating immune responses and has the potential to be a target for various inflammatory and neurological disorders by modulating the immune response and regulating the production of kynurenine deriva‐tives [69]. Due to tryptophan catabolism′s incredible impact on increasing immune sup‐pression, disparate small‐molecule inhibitors have been developed and tested in clinical trials [70–72]. Inflammatory cytokines and chemokines are key mediators of the immune response, and their release can lead to a cascade of effects that can disturb the immune Int. J. Mol. Sci. 2023, 24, 2737

5 of 17

adaptive natural reward circuits are activated in their brains. As such, addicted individuals
feel that drug abuse is part of their natural biological needs [58]. However, studies have
shown that multiple high-dose administrations of METH result in drug resistance in the
body, a phenomenon known as drug tolerance [59]. Levels of the tryptophan metabolite,
which is an amine precursor to serotonin, melatonin, kynurenine, and quinolinine pathways,
have been noted to be affected by METH addiction [60]. Decreased levels of tryptophan
have also been found to take place in suicidal adolescent patients [61]. Clinically, it is
known that METH toxicity affects nearly every organ system in the body, with the most
considerable damage occurring to the CNS [62]. This includes metabolic compromise,
oxidative stress, and inﬂammation of neurons resulting in neuronal death [63].

3. Tryptophan and Its Metabolites

Tryptophan is an important amino acid that plays a crucial role in various biological
processes, including in an infant(cid:48)s growth, muscle development, enzyme function, and
neurotransmitter regulation [64,65]. Tryptophan is a precursor to the metabolites serotonin,
melatonin, and kynurenine [66]. Most of the daily intake of tryptophan oxidizes down the
kynurenine pathway, whilst the rest degrades via serotonin pathways [67]. Tryptophan
is metabolized into serotonin and melatonin via the generation of 5-hydroxytryptophan,
which includes human peripheral tryptophan hydroxylase 1 (hpTrpH1) or human neural
tryptophan hydroxylase 2 (hnTrpH2), depending on whether metabolism occurs in pe-
ripheral entero-chromatic cells or neural cells of the CNS. 5-hydroxytryptophan is then
metabolized into serotonin and, further down, into melatonin via the action of different
enzymes [66,67]. The kynurenine pathway either involves the generation of kynurenic
acid (KA) or the formation of 3-hydroxy-anthranillic acid, further leading to quinolinic
acid (QA). These components, QA and KA, are believed to have noteworthy impacts on
CNS neurons. QA possesses the potential for application as a neurotoxin, while KA is a
neuroprotectant. 3-hydroxykynurenine is the third kynurenine metabolite that may create
free radicals and aggravate neuronal damage [68].

The kynurenine pathway plays a critical role in regulating immune responses and has
the potential to be a target for various inﬂammatory and neurological disorders by modu-
lating the immune response and regulating the production of kynurenine derivatives [69].
Due to tryptophan catabolism(cid:48)s incredible impact on increasing immune suppression, dis-
parate small-molecule inhibitors have been developed and tested in clinical trials [70–72].
Inﬂammatory cytokines and chemokines are key mediators of the immune response, and
their release can lead to a cascade of effects that can disturb the immune system and cause
a corresponding increase in kynurenine production [73,74]. An imbalance in kynurenine
production can shift the balance of tryptophan metabolism, resulting in the accumulation
of pro-inﬂammatory and neurotoxic kynurenine derivatives [75]. This can lead to a range
of negative effects, including increased susceptibility to infections, chronic inﬂammation,
and neurodegeneration. Furthermore, research has shown that the kynurenine pathway
is closely linked to various psychiatric and neurological disorders, including depression,
anxiety, schizophrenia, and Alzheimer(cid:48)s disease [76].

The kynurenine pathway involves 95% of tryptophan degradation in the liver via two
rate-limiting enzymes: indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-deoxygenase
(TDO) [77]. These enzymes, TDO and IDO, control tryptophan degradation through the
kynurenine pathway. TDO is primarily expressed in the liver and is responsible for the
initial degradation of tryptophan. This enzyme converts tryptophan into kynurenine,
which is then further metabolized by IDO. IDO is expressed in various tissues, includ-
ing the immune cells, and plays a key role in the regulation of immune responses. TDO
usually leads to nicotinamide dinucleotide (NAD+) in the liver only. However, IDO is
known to carry the same extra-hepatical reaction but in much smaller amounts than the
enzyme TDO [67]. Additionally, the combination of IDO1 inhibitors together with immune
checkpoint inhibitors, such as anti-programmed cell death 1 (PD1) and anti-programmed

Int. J. Mol. Sci. 2023, 24, 2737

6 of 17

cell death ligand 1 (PD-L1), have opened new avenues towards increasing the efﬁcacy of
immuno-oncology in cancer treatment [78–80].

The mammalian brain contains from nanomolar to low micromolar concentrations
of kynurenine pathway metabolites [81]. Acute stress causes an increase in tryptophan
metabolism to kynurenine in mice brains and plasma [82]. In fact, increased IDO en-
zyme activity and IdoI-v1 expression have been noted in the hypothalamus and frontal
cortex of the brain, speciﬁcally in astrocytes. Ferulic acid, a plant-derived phenol com-
pound with anti-inﬂammatory effects, has been shown to have suppressing effects on
lipopolysaccharide-induced IDO messenger RNA (mRNA) expression in mouse microglial
cells [83]. In addition, ferulic acid suppresses the phosphorylation of p38 MAPK and
the nuclear translocation of NF-κB [83]. Figure 2 schematically illustrates the tryptophan
metabolites, their pathways, and their effects on the CNS.

Figure 2. Schematic demonstration of tryptophan metabolites, its related disparate pathways, and its
metabolites(cid:48) effects on the central nervous system.

4. Tryptophan and Addiction: METH Addiction as an Example

Tryptophan is an essential amino acid that can only be obtained via dietary intake, and
a diet with low levels of tryptophan is related to malnutrition or poor diet habits [67]. Short-
term and long-term abuse of alcohol and its associated withdrawal is closely related to
tryptophan metabolism/disposition in humans and animals. Various studies have proved
that the activity of the rate-limiting enzyme of tryptophan degradation (liver tryptophan
pyrrolase) increases substantially during acute alcohol abuse and during withdrawal [84].
The occurrence of this alteration causes a signiﬁcant change in the synthesis process of
brain serotonin and the appropriate availability of tryptophan to the brain [84]. It has been
reported that serotonin can be considered the prominent tryptophan metabolite related
to psychiatric comorbidity in abstinent cocaine-addicted patients [40]. However, the non-
existence of efﬁcacious treatments following the great relapse rate among cocaine abusers
remains a major health problem.

METH (under the street names ice, crystal, glass, or kryptonite) is a potent synthetic
central nervous system (CNS) drug that has been placed second in rank of application in
the United States, Asia, and Oceania after cannabis [85,86]. METH is often sold in powder
or crystal form and is administered via intranasal snifﬁng, oral ingestion, pulmonary in-
halation, and injection. METH addiction leads to serious side effects on disparate organs

Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 6 of 18   system and cause a corresponding increase in kynurenine production [73,74]. An imbal‐ance in kynurenine production can shift the balance of tryptophan metabolism, resulting in the accumulation of pro‐inflammatory and neurotoxic kynurenine derivatives [75]. This can lead to a range of negative effects, including increased susceptibility to infections, chronic inflammation, and neurodegeneration. Furthermore, research has shown that the kynurenine pathway is closely linked to various psychiatric and neurological disorders, including depression, anxiety, schizophrenia, and Alzheimer′s disease [76]. The kynurenine pathway involves 95% of tryptophan degradation in the liver via two rate‐limiting enzymes: indoleamine 2,3‐dioxygenase (IDO) and tryptophan 2,3‐deox‐ygenase (TDO) [77]. These enzymes, TDO and IDO, control tryptophan degradation through the kynurenine pathway. TDO is primarily expressed in the liver and is respon‐sible for the initial degradation of tryptophan. This enzyme converts tryptophan into kynurenine, which is then further metabolized by IDO. IDO is expressed in various tis‐sues, including the immune cells, and plays a key role in the regulation of immune re‐sponses. TDO usually leads to nicotinamide dinucleotide (NAD+) in the liver only. How‐ever, IDO is known to carry the same extra‐hepatical reaction but in much smaller amounts than the enzyme TDO [67]. Additionally, the combination of IDO1 inhibitors together with immune checkpoint inhibitors, such as anti‐programmed cell death 1 (PD1) and anti‐programmed cell death ligand 1 (PD‐L1), have opened new avenues towards increasing the efficacy of immuno‐oncology in cancer treatment [78–80]. The mammalian brain contains from nanomolar to low micromolar concentrations of kynurenine pathway metabolites [81]. Acute stress causes an increase in tryptophan me‐tabolism to kynurenine in mice brains and plasma [82]. In fact, increased IDO enzyme activity and IdoI‐v1 expression have been noted in the hypothalamus and frontal cortex of the brain, specifically in astrocytes. Ferulic acid, a plant‐derived phenol compound with anti‐inflammatory effects, has been shown to have suppressing effects on lipopolysaccha‐ride‐induced IDO messenger RNA (mRNA) expression in mouse microglial cells [83]. In addition, ferulic acid suppresses the phosphorylation of p38 MAPK and the nuclear trans‐location of NF‐κB [83]. Figure 2 schematically illustrates the tryptophan metabolites, their pathways, and their effects on the CNS.  Figure 2. Schematic demonstration of tryptophan metabolites, its related disparate pathways, and its metabolites′ effects on the central nervous system. Int. J. Mol. Sci. 2023, 24, 2737

7 of 17

within the human body, such as subjective euphoria/arousal, chronic depression, and
psychomotor activation [87,88]. Poor mental health and social disability (i.e., unemploy-
ment and economic hardship) can be considered the most immediate adverse effects of
METH dependence, which signiﬁcantly decreases the quality of life among users [89,90].
METH dependence is a major global public health challenge due to its medical, psychiatric,
cognitive, and socioeconomic consequences [91,92]. Figure 3 represents the METH-induced
serotonin pathway in the CNS.

Figure 3. Methamphetamine (METH) administration leads to a detrimental effect on the serotonin
pathway in the central nervous system [Figure created with BioRender.com].

Weekly stimulant use of recreational drugs such as METH, cocaine, etc., results in de-
creased levels of tryptophan. Suicidal adolescent patients suffering from major depressive
disorder have decreased levels of circulating tryptophan [61], and suicidality/depression
is considered one of the symptoms of METH addiction. Overall, research has shown that
METH abuse affects the CNS, the spleen, the gut, and the liver [60]. Damage to these organ
systems can also adversely affect tryptophan metabolism pathways, causing an imbalance
in the levels of its metabolites. The effect of METH on tryptophan and its metabolites and
the associated consequences are brieﬂy discussed below.

4.1. Serotonin (5-hydroxytryptophan)

Hydroxylation of L-tryptophan leads to the formation of L-5-hydroxytryptophan
(L-5HT) via the action of tryptophan hydroxylase. Aromatic amino acid de-carboxylate
helps convert L-5HT to serotonin 5-HT. Tryptophan hydroxylase 1 (TPH1) is known to be
composed of two types of TPH enzymes, and is responsible for 95% of the body’s 5-HT
formation in the gut, which can travel to all body organs via the blood except for the brain,
as it cannot pass through the blood–brain barrier. TPH2 helps the formation of 5-HT in
the brain along with the action of aromatic l-amino acid decarboxylase (AADC) [93]. It
has been shown that tryptophan hydroxylase activity increases in the globus pallidus,
nucleus accumbens, and the caudate area within 1 h of a single bout of METH. However,
long-term multiple METH doses only decreased TPH2 activity in the caudate area but not
in the nucleus accumbens and globus pallidus [94]. However, recently, it was noted that
TPH2 gene variants are not a factor in vulnerability to METH psychosis/dependence as no
genotypic/allelic changes are observed between METH-dependent patients (n = 162) and
controls (n = 243) [95].

Further experiments would aid in the understanding of why there is a lack of corre-
lation between long-term and short-term METH use around the activity of TPH2 in the

Int. J. Mol. Sci. 2023, 24, x FOR PEER REVIEW 7 of 18   4. Tryptophan and Addiction: METH Addiction as an Example Tryptophan is an essential amino acid that can only be obtained via dietary intake, and a diet with low levels of tryptophan is related to malnutrition or poor diet habits [67]. Short‐term and long‐term abuse of alcohol and its associated withdrawal is closely related to tryptophan metabolism/disposition in humans and animals. Various studies have proved that the activity of the rate‐limiting enzyme of tryptophan degradation (liver tryp‐tophan pyrrolase) increases substantially during acute alcohol abuse and during with‐drawal [84]. The occurrence of this alteration causes a significant change in the synthesis process of brain serotonin and the appropriate availability of tryptophan to the brain [84]. It has been reported that serotonin can be considered the prominent tryptophan metabo‐lite related to psychiatric comorbidity in abstinent cocaine‐addicted patients [40]. How‐ever, the non‐existence of efficacious treatments following the great relapse rate among cocaine abusers remains a major health problem. METH (under the street names ice, crystal, glass, or kryptonite) is a potent synthetic central nervous system (CNS) drug that has been placed second in rank of application in the United States, Asia, and Oceania after cannabis [85,86]. METH is often sold in powder or crystal form and is administered via intranasal sniffing, oral ingestion, pulmonary in‐halation, and injection. METH addiction leads to serious side effects on disparate organs within the human body, such as subjective euphoria/arousal, chronic depression, and psy‐chomotor activation [87,88]. Poor mental health and social disability (i.e., unemployment and economic hardship) can be considered the most immediate adverse effects of METH dependence, which significantly decreases the quality of life among users [89,90]. METH dependence is a major global public health challenge due to its medical, psychiatric, cog‐nitive, and socioeconomic consequences [91,92]. Figure 3 represents the METH‐induced serotonin pathway in the CNS.  Figure 3. Methamphetamine (METH) administration leads to a detrimental effect on the serotonin pathway in the central nervous system [Figure created with BioRender.com]. Weekly stimulant use of recreational drugs such as METH, cocaine, etc., results in decreased levels of tryptophan. Suicidal adolescent patients suffering from major depres‐sive disorder have decreased levels of circulating tryptophan [61], and suicidality/depres‐sion is considered one of the symptoms of METH addiction. Overall, research has shown that METH abuse affects the CNS, the spleen, the gut, and the liver [60]. Damage to these organ systems can also adversely affect tryptophan metabolism pathways, causing an im‐balance in the levels of its metabolites. The effect of METH on tryptophan and its metab‐olites and the associated consequences are briefly discussed below. Int. J. Mol. Sci. 2023, 24, 2737

8 of 17

nucleus accumbens and globus pallidus regions of the brain. Despite this, a decrease in
TPH2 levels is observed in the caudate area in both short- and long-term METH administra-
tion. These studies show that the decrease in TPH2 activity occurs in different brain regions,
and it is plausible to argue that a decrease in TPH2 levels in the brain could be responsible
for low 5-HT levels. It is essential to keep in mind that other factors/molecular mechanisms
could also be responsible for low 5-HT levels in the CNS, such as tolerance-related 5-HT
deﬁcits in the brain [59].

4.2. Melatonin

Melatonin is a metabolite of serotonin that is formed via the serotonin pathway through
the action of enzymes aralkylamine N-acetyltransferase (AA-NAT) and hydroxyindole-O-
methyltransferase (HIOMT). After its formation in the pinealocytes of the pineal gland, it
is transferred to the blood and cerebrospinal ﬂuid of the brain, where second messengers
of sleep are initiated in order to cause sleepiness [67]. Melatonin is formed through the
metabolism of serotonin. Therefore, a decrement in serotonin levels would mean a decrease
in melatonin levels in METH addicts [57,96]. As such, serotonin is also known to regulate
sleep–wake cycles [67], which would explain the disturbance in the sleep cycles of METH
addicts. Overall, amphetamine abuse is known to be linked to disturbances in sleep cycles,
with chronic abuse being more detrimental than the usual acute abuse of drug addiction [97].
A study in rhesus macaques showed disrupted wake cycles and poor sleep efﬁciency after
both low and high METH self-administration [98].

4.3. Kynurenine

The metabolism of tryptophan forms kynurenine via the action of the enzymes IDO
and TDO [61]. Kynurenine is not known to be neuroactive but can cross the blood–brain
barrier to aid in the formation of free radicals producing 3-hydroxyanthranillic acid, 3-
hydroxykynurenine, or quinolinic acid. It has also been shown that depressed, suicidal
patients have decreased kynurenine plasma levels [61], and suicidality is one of the major
symptoms of METH addiction. Pro-inﬂammatory cytokines are known to further help
kynurenine metabolism and cause an increase in the levels of its metabolites [66]. Alter-
ations in the evel of the kynurenine pathway metabolites are known as a major cause of
neurotoxicity [99]. Over-activation of the IDO and TDO enzymes is known to cause the
degradation of most of the tryptophan along the kynurenine pathway. Thus, this leads to
lower levels of serotonin via the upregulation of tryptophan along the kynurenine pathway,
which is thought to be one of the reasons for the occurrence of depression [99].

4.4. Kynurenic Acid

The action of kynurenine aminotransferase on kynurenine leads to the formation of
kynurenic acid, which takes place in the neurons, astrocytes, and oligodendrocytes of the
CNS. Once it is synthesized, it is released into the extracellular spaces to act on its pre-
and post-synaptic targets [67]. Physiologically, kynurenic acid has a neuroprotective role
as it helps prevent pro-inﬂammatory cytokines, but its elevated levels are known to be
linked to psychosis and cognitive deﬁcits [66]. It also inhibits the alpha-7 nicotinic receptor
because the receptor, when activated by its agonist, is known to have cognitive-enhancing
effects [100]. Kynurenic acid is also known to stabilize the levels of free radicals within the
CNS [66]. D-amphetamine, an enantiomer of amphetamine, when systematically adminis-
tered to rats of different ages, causes a decrease in the extracellular levels and tissue content
of kynurenic acid in the brain within 1 h following D-amphetamine administration [101].
Schizophrenic patients with psychosis and a history of suicide have lower cerebrospinal
ﬂuid kynurenic acid concentrations [102]. However, patients with schizophrenia only have
relatively higher levels of kynurenic acid levels in cerebrospinal ﬂuid when compared with
healthy individuals [66]. This shows that depression/suicidality can lead to lower levels of
kynurenic acid. Kynurenic acid is known to act as an antagonist for glutamatergic NMDA
receptors. Trihexyphenidyl is known to antagonize the METH-induced reward pathway

Int. J. Mol. Sci. 2023, 24, 2737

9 of 17

via the suppression of dopamine release from the mesolimbic area [103]. Present data show
that high levels of kynurenic acid can prove to be beneﬁcial in the CNS of METH addicts,
but kynurenic acid is found to be low in suicidal depressive and psychotic patients, which
are common major symptoms of METH addiction.

4.5. Xanthurenic Acid

The catabolism of the 3-hydroxykynurenine forms xanthurenic acid via the action
of kynurenine aminotransferase. It is also considered an analog of kynurenic acid and
is thus also known to have neuroprotective functions. It is thought to be localized in
the cell body and dendrites of neurons but not in the axons, which is why there are
debates on whether xanthurenic acid has a role in neurotransmission in the CNS [104].
However, the upregulation of xanthurenic acid in the CNS leads to a decreased synthesis of
neurotransmitters such as serotonin and dopamine [105]. In addition, levels of depression
and levels of xanthurenic acid positively correlate with each other in the urine of patients
with depression [106]. Some initial studies also show that xanthurenic acid may act as
an allosteric agonist for the metabotropic glutamate receptors type 2 and 3, but further
research is required to support this ﬁnding. Along with xanthurenic acid, they are known
to act as inhibitors for vesicular glutamatergic transporters whose immediate action is the
prevention of glutamate reuptake from the synaptic vessels [107]. A similar mechanism
takes place via METH in the neural synapses of a METH addict(cid:48)s CNS neurons. The
current data show that while xanthurenic acid may have neuroprotective characteristics, its
upregulation has similar effects as those seen in METH addicts. Therefore, future research
on xanthurenic acid in the context of METH addiction will aid in a better understanding of
the neural actions of xanthurenic acid in the CNS.

4.6. 3-hydroxyanthranillic Acid

In the CNS, 3-hydroxyanthranillic acid is formed via the action of kynureninase on
anthranilic acid, whereas in the periphery, it is formed from 3-hydroxykynurenine [66].
3-hydroxyanthranillic acid is a very reactive compound that can either act as an antioxidant
or pro-oxidant depending on the redox reactions in the brain. One study showed no notable
differences in the plasma levels of 3-hydroxyanthranillic acid between suicidal depressed
and healthy control groups [61]. However, a positive correlation between the levels of
3-hydroxyanthranillic acid and choline were noted; choline is responsible for cell mem-
brane breakdown in melancholic depressive patients [66]. Inhibition of kynurenine in the
kynurenic acid pathway leads to increased production of 3-hydroxyanthranillic acid [108],
and since depressive patients have low levels of kynurenic acid in their brains [102], it is
possible that depressive patients have high levels of 3-hydroxyanthranillic acid. Based
on this, it can be hypothesized that depression can be caused by METH abuse, and 3-
hydroxyanthranillic acid levels would be higher in depressive METH addicts. Further
research, however, is required to better understand the relationships between METH
addiction, depression, and 3-hydroxyanthranillic acid.

4.7. Quinolinic Acid

Quinolinic acid is formed from 3-hydroxyanthranillic acid via the action of enzyme
3-hydroxyanthranillic acid oxygenase. Quinolinic acid is mainly thought to be produced in
the brain by microglial cells and by inﬁltrating macrophages and is thought to be neurotoxic
via several different mechanisms [66]. Quinolinic acid is known to severely impair energy
metabolism in the striatum of developing rats via the activation of NMDA receptors [109].
Quinolinic acid has also been known to cause an increase in the release of glutamate
while preventing its reuptake from the synaptic vesicles in individuals [110]. Quinolinic
levels have been found to be very high in the cerebrospinal ﬂuid of depressed suicide
attempters [111]. High levels of quinolinic acid correlate with interleukin (IL)-6, suggesting
that high levels of quinolinic acid may be due to inﬂammatory responses [112]. In addition,
quinolinic acid levels are high in the cortical and subcortical regions of psychiatric suicidal

Int. J. Mol. Sci. 2023, 24, 2737

10 of 17

patients [113]. In fact, ketamine, an NMDA receptor antagonist, helps overcome suicidal
thoughts [114]. However, even though ketamine can act as an antagonist for the NMDA re-
ceptor, a balanced ratio of quinolinic acid/kynurenic acid can be more effective in avoiding
depression with respect to the NMDA receptor because both the acids can act as an agonist
(quinolinic acid) and antagonist (kynurenic acid) for the receptor [111]. D-amphetamine, an
enantiomer of amphetamine, is known to cause a decrease in levels of kynurenic acid [101].
As such, it is plausible to argue that a decrease in kynurenic acid would push tryptophan
metabolism towards quinolinic acid and, thus, raise the concentration of quinolinic acid,
which would support the fact that quinolinic acid is one of the factors responsible for
depression/suicidality in METH addicts.

4.8. Picolinic Acid

When the enzyme 2-amino-3-carboxymuconic-6-semialdehyde decarboxylase (ACMSD)

acts on ACMS, rather than forming quinolinic acid spontaneously, it instead forms picolinic
acid [66]. It is not known whether picolinic acid is able to cross the blood–brain barrier or
not, but it can be easily detected in human cerebrospinal ﬂuid [115].

ACMSD is also present in glial and neuronal cells of the cortex and hippocampus [113];
hence, picolinic acid can be produced in the brain. A study showed that picolinic acid
can antagonize the neurotoxic effects of quinolinic acid, as well as having neuroprotective
properties [116]. In depressed suicide attempters, picolinic acid levels in the cerebrospinal
ﬂuid are known to signiﬁcantly drop when compared with the levels in healthy individ-
uals, which is linked to a drop in the actions of the ACMSD enzyme [117]. This means
that an increase in quinolinic acid levels will occur because 2-amino-3-carboxymuconic-
6-semialdehyde spontaneously converts to quinolinic acid in the absence of the ACMSD
enzyme. Based on these ﬁndings, it can be concluded that lower levels of picolinic acid
can be expected in the brains and bodies of people with METH addiction. However, the
relationship between picolinic acid and METH addiction is not fully known, and further
studies will provide a better understanding of this relationship.

4.9. Nicotinamide Adenine Dinucleotide (NAD+)

Nicotinamide adenine dinucleotide (NAD+) is formed from the metabolism of quino-
linic acid via the action of quinolinic acid phosphoribosyl transferase [61]. The TDO enzyme
of the tryptophan pathway, which is known to carry out most of the metabolism in the
tryptophan pathway in the liver, also leads to the formation of NAD+. It is also considered
to have a signiﬁcant role in the maintenance of cell viability [67]. In one study in mice,
which were forced to swim, it was noted that NAD+ had anti-depressant effects in mice
after they were stressed [118]. NAD+ is also found to be an important co-enzyme in many
oxidation–reduction reactions [67]. It is also responsible for cell homeostasis and energy
metabolism, thus making it an important cellular molecule that is a regulator of the circa-
dian cycle [119]. NAD+ can have positive effects in METH addicts who suffer from suicidal
depression, but further research is required to explore the correlation between NAD+ and
METH-induced neuronal damage.

4.10. Reactive Oxygen and Nitrogen Species

Reactive oxygen (ROS) and nitrogen species (RNS) are produced as by-products of the
tryptophan metabolism pathway. Increases in ROS and RNS are known to be responsible
for oxidative stress and nitrosative stress in the body, and this oxidative stress has been
linked to anxiety, depression, and inﬂammatory responses. RNS and ROS usually include
superoxide, nitric oxide, and hydrogen peroxide [120]. Based on this, increases in levels
of RNS and ROS are very likely in the CNSs of METH addicts. It has also been noted that
decreased levels of the antioxidative compound glutathione also occur in victims of major
depressive disorder [121]. Due to this, antidepressants that target the production of RNS
and ROS are currently being explored, which includes inhibiting the over-production of
RNS and ROS along with suppressing their inﬂammatory effects [122]. METH affects the

Int. J. Mol. Sci. 2023, 24, 2737

11 of 17

balance of tryptophan and its metabolites signiﬁcantly, and further research on each of the
pathways will be constructive towards the development of new therapeutics, which will
aid in evading the detrimental effects of METH on the tryptophan metabolism pathways.

5. Tryptophan Metabolites and Treatment Options for Addiction

Acute/chronic addiction to alcohol has signiﬁcant impacts on tryptophan metabolism
in human and animal subjects. Tryptophan has been studied in relation to alcohol addiction
because it is the precursor of indolylamine serotonin, which controls disparate functions
in the CNS such as mood and depression [123,124]. It was corroborated in the mid-1980s
that 5-HT had the ability to control the abnormal tendency to drink alcohol [84]. In animal
studies, the presence of low central 5-HT concentration in various animal models was
an interesting aspect of tryptophan metabolism related to alcohol addiction [125]. This
deﬁciency is of great importance in alcohol-abuse behavior. The increasing trend of cocaine
abuse has been a major health issue associated with millions of people(cid:48)s dependency and
high social costs [126,127]. Numerous studies have investigated the mechanism of action
of cocaine, with no efﬁcacious treatments for patients and compulsive users [128]. A small
amount of tryptophan is used for 5-HT synthesis, while a greater proportion is metabo-
lized via the kynurenine pathway manufacturing biologically active metabolites such as
kynurenic acid, 3-hydroxykynurenine, and quinolinic acid. While 3-hydroxykynurenine
and quinolinic acid are neurotoxic metabolites, kynurenic acid is thought to be involved in
neuroprotection. Due to the great inﬂuence of 5-HT in the pathogenesis of mood disorders,
the relationship between neurotoxic and neuroprotective metabolites of tryptophan is of
great importance [129]. Currently, the pharmacological increase in kynurenic acid has been
under extensive investigation as a new and promising option for treating those patients
suffering from compulsive abuse of marijuana and nicotine dependency [40,130,131]. It
has been corroborated that kynurenic acid can play an important role in relapse-like situa-
tions owing to its enhancement of an abrogating cocaine-seeking demeanor [131]. Table 2
presents information regarding the most commonly used addictive substances and their
associated tryptophan metabolites.

Table 2. Summary of common addictive substances and their associated tryptophan metabolites.

Drug

METH
Alcohol
Marijuana
Heroin
Nicotine
Caffeine
Cocaine

Tryptophan Metabolite

5-HT, KA, and QA
5-HT, KA, 3-HK, and 3-HAA
IDO 1, KA, and QA
QA and 5-HIAA
KA, 5-HT, KYN, HKY, and 3-HAA
KA, 5-HT, 5-HIAA, and QA
KA, KYN, 5-HT, and 5-HIAA

Ref.

[132,133]
[84,123]
[134,135]
[136]
[137]
[138,139]
[140,141]

Abbreviations:
IDO, indoleamine 2,3-deoxygenase; KA, kynurenic acid; KYN, kynurenine; L-5HT, L-5-
hydroxytryptophan; METH, methamphetamine; QA, Quinolinic acid; 3-HAA, 3-hydroxyanthranillic acid; 5-HIAA,
5-hydroxyindoleacetic acid.

6. Conclusions

This review evaluated the detrimental effects of addictive substances, speciﬁcally
METH, on human mental and psychological dependency. The role of METH and other
addictive substances in mental and psychological dependency in humans was presented,
along with a description of tryptophan metabolites in the mammalian brain and their
potential as new treatment options for controlling compulsive substance abuse. Tobacco
smoke signiﬁcantly increases the potential hazard of different chronic diseases such as lung
diseases, heart failure, brain stroke, and chronic obstructive pulmonary diseases. The abuse
of marijuana may result in various unfavorable side effects, such as the risk of permanent
IQ loss, depression, and suicide planning. In the last ﬁve years, vaping has become popular,
especially among the youth, and health issues and severe complications have already been
reported; one awaits the addictive behaviors and health issues due to its use in the coming

Int. J. Mol. Sci. 2023, 24, 2737

12 of 17

years. In the case of alcohol, it is worth mentioning that the long-term abuse of this addic-
tive substance may cause the emergence of disparate chronic diseases such as high blood
pressure, a decrease in the performance of the immune system, and digestive problems.
Despite detrimental long-term results related to METH and other addictive substances,
numerous people use them to alleviate short-term physical/emotional sensations. By elimi-
nating these unfavorable states, drug-use behaviors are negatively reinforced. Abstinence
from METH may cause a return to former undesirable emotional states that are associ-
ated with craving, usually leading to an elevated probability of relapse. The functional
effects of METH on tryptophan and its disparate metabolites, including serotonin 5-HT
(5-hydroxytryptophan), melatonin, kynurenine, and reactive oxygen and nitrogen species,
as well as the formation and structure of each, were examined. Understanding the connec-
tions between tryptophan metabolites and addiction provides a valuable opportunity to
investigate future perspectives on developing promising modalities for addiction treatment.
The compulsive abuse of addictive substances as active CNS stimulants eventuates thse
emergence of serious side effects such as poor mental/physical health and socio-economic
challenges. Tryptophan metabolites show potential for application as new treatment op-
tions to manage compulsive abuse of addictive substances. Moreover, several studies have
reported the development of vaccines against METH addiction [142–144], but none have
been translated into human clinical trials yet. The identiﬁcation of tryptophan metabolites
as potential treatment options for addiction, in combination with new approaches such as
vaccines, may lead to more effective methods for managing compulsive substance abuse in
the future.

Author Contributions: Conceptualization, V.A. and K.N.; writing—original draft preparation, M.D.
and N.R.; writing—review and editing, V.A., A.R., M.K.H., and M.D.; supervision, K.N. and V.A. All
authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is
not applicable to this article.

Acknowledgments: The authors would also like to thank the Immunology and Translational Re-
search Group and the Intestinal Neuropathy Group for their ongoing discussions. The Institute for
Health and Sport, Victoria University Australia is also appreciated for its support. M.D., N.R., and
M.K.H were supported by the Victoria University Postgraduate Scholarships.

Conﬂicts of Interest: The authors declare no conﬂict of interest.

References

1.

2.
3.
4.
5.

Goldstein, R.; Volkow, N. Dysfunktion av prefrontal cortex i missbruk: Neuroimaging fynd och kliniska konsekvenser. Nat. Rev.
Neurosci. 2011, 12, 652–669. [CrossRef]
Volkow, N.D.; Li, T.-K. Drug addiction: The neurobiology of behaviour gone awry. Nat. Rev. Neurosci. 2004, 5, 963–970. [CrossRef]
Barnard, M. Drug Addiction and Families; Jessica Kingsley Publishers: London, UK, 2006.
Ihezie, S.A.; Dafny, N. Prevention of Opioid Addiction. J. ISSN 2021, 2766, 2276. [CrossRef]
Pantoni, M.M.; Kim, J.L.; Van Alstyne, K.R.; Anagnostaras, S.G. MDMA and memory, addiction, and depression: Dose-effect
analysis. Psychopharmacology 2022, 239, 935–949. [CrossRef] [PubMed]

6. Heilig, M.; Augier, E.; Pfarr, S.; Sommer, W.H. Developing neuroscience-based treatments for alcohol addiction: A matter of

7.

choice? Transl. Psychiatry 2019, 9, 255. [CrossRef]
Adams, M.K.; Chong, E.W.; Williamson, E.; Aung, K.Z.; Makeyeva, G.A.; Giles, G.G.; English, D.R.; Hopper, J.; Guymer, R.H.;
Baird, P.N. 20/20—Alcohol and age-related macular degeneration: The Melbourne Collaborative Cohort Study. Am. J. Epidemiol.
2012, 176, 289–298. [CrossRef] [PubMed]

8. Nwokike, M.; Anusiem, C.; Arinze, C.; Ogbonna, A. The Abuse of Central Nervous System Stimulants and its Impact on the

Youth of Eastern Nigeria. Int. Neuropsychiatr. Dis. J. 2021, 15, 20–33. [CrossRef]

9. White, E.; Comiskey, C. Heroin epidemics, treatment and ODE modelling. Math. Biosci. 2007, 208, 312–324. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2023, 24, 2737

13 of 17

10. Carmack, S.A.; Keeley, R.J.; Vendruscolo, J.C.; Lowery-Gionta, E.G.; Lu, H.; Koob, G.F.; Stein, E.A.; Vendruscolo, L.F. Heroin

addiction engages negative emotional learning brain circuits in rats. J. Clin. Investig. 2019, 129, 2480–2484. [CrossRef]

11. Ritter, A.; Cao, V.L.; Shanahan, M.; Shukla, N.; Perez, P.; Farrell, M. Modelling heroin careers over 40 years: Social costs. Drug

Alcohol Depend. 2017, 100, e177. [CrossRef]

12. Walsh, J.M. Are we there yet? Measuring Progress in the US War on Drugs in Latin America. WOLA Drug War Monit. 2004, 8.
13. Hser, Y.-I. Predicting long-term stable recovery from heroin addiction: Findings from a 33-year follow-up study. J. Addict. Dis.

2007, 26, 51–60. [CrossRef]

14. Dani, J.A.; Harris, R.A. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat. Neurosci. 2005, 8,

15.

16.
17.

1465–1470. [CrossRef] [PubMed]
Scarlata, M.; Keeley, R.; Stein, E. Nicotine addiction: Translational insights from circuit neuroscience. Pharmacol. Biochem. Behav.
2021, 204, 173171. [CrossRef] [PubMed]
Fagerström, K. Nicotine: Pharmacology, toxicity and therapeutic use. J. Smok. Cessat. 2014, 9, 53–59. [CrossRef]
Jetton, J.A.; Ding, K.; Kim, Y.; Stone, D.U. Effects of tobacco smoking on human corneal wound healing. Cornea 2014, 33, 453–456.
[CrossRef]

18. Antonelli, M.; Ferrulli, A.; Sestito, L.; Vassallo, G.A.; Tarli, C.; Mosoni, C.; Rando, M.M.; Mirijello, A.; Gasbarrini, A.; Addolorato,

G. Alcohol addiction-the safety of available approved treatment options. Expert Opin. Drug Saf. 2018, 17, 169–177. [CrossRef]

19. Gibbins, R.J. Chronic Alcoholism and Alcohol Addiction; University of Toronto Press: Toronto, ON, USA, 2019.
20. Behling, M.; Winters, B. Methods to Stop Caffeine Use and Minimize Caffeine Withdrawal Symptoms in the State of Caffeine
Dependence: A Literature Review. Stud. Works 2021. Available online: https://scholarsarchive.byu.edu/cgi/viewcontent.cgi?
article=1363&context=studentpub (accessed on 3 January 2023).
Favrod-Coune, T.; Broers, B. Addiction to caffeine and other xanthines.
Berlin/Heidelberg, Germany, 2021; pp. 215–228.

In Textbook of Addiction Treatment; Springer:

21.

22. Alasmari, F. Caffeine induces neurobehavioral effects through modulating neurotransmitters. Saudi Pharm. J. 2020, 28, 445–451.

[CrossRef]

23. Chandio, Z.A.; Sidiqua, A.; Khaskheli, M.I.; Waghani, A.; Metlo, W.A. Review Effect of Caffeine Overdose. RADS J. Biol. Res. Appl.

Sci. 2020, 11, 152–156. [CrossRef]

24. Riezzo, I.; Fiore, C.; De Carlo, D.; Pascale, N.; Neri, M.; Turillazzi, E.; Fineschi, V. Side effects of cocaine abuse: Multiorgan toxicity

and pathological consequences. Curr. Med. Chem. 2012, 19, 5624–5646. [CrossRef]

25. Pierce, R.C.; Fant, B.; Swinford-Jackson, S.E.; Heller, E.A.; Berrettini, W.H.; Wimmer, M.E. Environmental, genetic and epigenetic

contributions to cocaine addiction. Neuropsychopharmacology 2018, 43, 1471–1480. [CrossRef]

27.

26. Valencia-Alfonso, C.-E.; Luigjes, J.; Smolders, R.; Cohen, M.X.; Levar, N.; Mazaheri, A.; van den Munckhof, P.; Schuurman, P.R.;
van den Brink, W.; Denys, D. Effective deep brain stimulation in heroin addiction: A case report with complementary intracranial
electroencephalogram. Biol. Psychiatry 2012, 71, e35–e37. [CrossRef] [PubMed]
Sarajlija, M.; Raketic, D.; Nesic, N. Heroin addiction in Serbian patients with Tourette syndrome. J. Psychiatr. Pract. 2018, 24,
424–427. [CrossRef]
Sabet, K. Marijuana and legalization impacts. Berkeley J. Crim. L. 2018, 23, 84.

28.
29. Ethan, X.; Logan, A.; Liam, M.; Leonard, J. Impact of Marijuana (Cannabis) on Health, Safety and Economy. Int. Digit. Organ. Sci.

30.

Res. (IDOSR) J. Exp. Sci. 2020, 5, 43–52.
Sun, X.; Xu, C.S.; Chadha, N.; Chen, A.; Liu, J. Focus: Addiction: Marijuana for Glaucoma: A Recipe for Disaster or Treatment?
Yale J. Biol. Med. 2015, 88, 265–269.

31. Temmingh, H.S.; van den Brink, W.; Howells, F.; Sibeko, G.; Stein, D.J. Methamphetamine use and antipsychotic-related

extrapyramidal side-effects in patients with psychotic disorders. J. Dual Diagn. 2020, 16, 208–217. [CrossRef]

32. Dhein, S.; Schmelmer, K.; Guenther, J.; Salameh, A. Aspects of methamphetamine abuse in adolescents and young adults in a

Thuringian County. Eur. Addict. Res. 2018, 24, 98–105. [CrossRef]

33. Naji, L.; Dennis, B.; Rosic, T.; Wiercioch, W.; Paul, J.; Worster, A.; Thabane, L.; Samaan, Z. Mirtazapine for the treatment
of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022,
232, 109295. [CrossRef]

34. Escobar-Chávez, J.J.; Domínguez-Delgado, C.L.; Rodríguez-Cruz, I.M. Targeting nicotine addiction: The possibility of a therapeu-

35.

36.
37.

tic vaccine. Drug Des. Dev. Ther. 2011, 5, 211–224. [CrossRef]
Sliwi ´nska-Mosso ´n, M.; Ziele ´n, I.; Milnerowicz, H. New trends in the treatment of nicotine addiction. Acta Pol. Pharm. 2014, 71,
525–530. [PubMed]
Jamali, Q. Galantamine as a Treatment Option for Nicotine Addiction. J. Smok. Cessat. 2021, 2021, 9975811. [CrossRef] [PubMed]
Stewart, S.H.; Walitzer, K.S.; Blanco, J.; Swiatek, D.; Paine Hughes, L.; Quiñones-Lombraña, A.; Shyhalla, K. Medication-enhanced
behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation. J.
Subst. Abus. Treat. 2019, 104, 7–14. [CrossRef]
Saunders, E.C.; McGovern, M.P.; Lambert-Harris, C.; Meier, A.; McLeman, B.; Xie, H. The impact of addiction medications on
treatment outcomes for persons with co-occurring PTSD and opioid use disorders. Am. J. Addict. 2015, 24, 722–731. [CrossRef]
39. Kału ˙zna-Czapli ´nska, J.; G ˛atarek, P.; Chirumbolo, S.; Chartrand, M.S.; Bjørklund, G. How important is tryptophan in human

38.

health? Crit. Rev. Food Sci. Nutr. 2019, 59, 72–88. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2023, 24, 2737

14 of 17

40. Araos, P.; Vidal, R.; O’Shea, E.; Pedraz, M.; García-Marchena, N.; Serrano, A.; Suárez, J.; Castilla-Ortega, E.; Ruiz, J.J.; Campos-
Cloute, R.; et al. Serotonin is the main tryptophan metabolite associated with psychiatric comorbidity in abstinent cocaine-addicted
patients. Sci. Rep. 2019, 9, 16842. [CrossRef]

41. Bamia, C.; Trichopoulou, A.; Lenas, D.; Trichopoulos, D. Tobacco smoking in relation to body fat mass and distribution in a

general population sample. Int. J. Obes. 2004, 28, 1091–1096. [CrossRef]

42. Harris, K.K.; Zopey, M.; Friedman, T.C. Metabolic effects of smoking cessation. Nat. Rev. Endocrinol. 2016, 12, 299–308. [CrossRef]

[PubMed]

43. Arterberry, B.J.; Treloar, H.R.; Smith, A.E.; Martens, M.P.; Pedersen, S.L.; McCarthy, D.M. Marijuana use, driving, and related

cognitions. Psychol. Addict. Behav. 2013, 27, 854–860. [CrossRef]

44. Gottlieb, E. Cannabis: A Danger to the Adolescent Brain—How Pediatricians Can Address Marijuana Use; Citeseer: University Park, PA,

USA, 2012.

45. Roerecke, M.; Vafaei, A.; Hasan, O.S.M.; Chrystoja, B.R.; Cruz, M.; Lee, R.; Neuman, M.G.; Rehm, J. Alcohol Consumption and

Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2019, 114, 1574–1586. [CrossRef]

46. Nawrot, P.; Jordan, S.; Eastwood, J.; Rotstein, J.; Hugenholtz, A.; Feeley, M. Effects of caffeine on human health. Food Addit.

47.

Contam. 2003, 20, 1–30. [CrossRef]
Saimaiti, A.; Zhou, D.D.; Li, J.; Xiong, R.G.; Gan, R.Y.; Huang, S.Y.; Shang, A.; Zhao, C.N.; Li, H.Y.; Li, H.B. Dietary sources, health
beneﬁts, and risks of caffeine. Crit. Rev. Food Sci. Nutr. 2022, 1–19. [CrossRef] [PubMed]

48. Hswen, Y.; Zhang, A.; Brownstein, J.S. Estimating the incidence of cocaine use and mortality with music lyrics about cocaine. NPJ

Digit. Med. 2021, 4, 100. [CrossRef] [PubMed]

49. Won, S.; Hong, R.A.; Shohet, R.V.; Seto, T.B.; Parikh, N.I. Methamphetamine-Associated Cardiomyopathy. Clin. Cardiol. 2013, 36,

737–742. [CrossRef] [PubMed]

51.

50. Davidson, M.; Mayer, M.; Habib, A.; Rashidi, N.; Filippone, R.T.; Fraser, S.; Prakash, M.D.; Sinnayah, P.; Tangalakis, K.; Mathai,
M.L.; et al. Methamphetamine Induces Systemic Inﬂammation and Anxiety: The Role of the Gut–Immune–Brain Axis. Int. J. Mol.
Sci. 2022, 23, 11224. [CrossRef]
Sulzer, D.; Sonders, M.S.; Poulsen, N.W.; Galli, A. Mechanisms of neurotransmitter release by amphetamines: A review. Prog.
Neurobiol. 2005, 75, 406–433. [CrossRef] [PubMed]
Fu, M.; Wang, C.; Zhang, X.; Pestell, R.G. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol.
2004, 68, 1199–1208. [CrossRef]

52.

53. Prakash, M.D.; Tangalakis, K.; Antonipillai, J.; Stojanovska, L.; Nurgali, K.; Apostolopoulos, V. Methamphetamine: Effects on the

brain, gut and immune system. Pharmacol. Res. 2017, 120, 60–67. [CrossRef]

54. Papageorgiou, M.; Raza, A.; Fraser, S.; Nurgali, K.; Apostolopoulos, V. Methamphetamine and its immune-modulating effects.

55.

Maturitas 2019, 121, 13–21. [CrossRef]
Surratt, C.K.; Ukairo, O.T.; Ramanujapuram, S. Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic
neurotransmitter uptake by the plasma membrane monoamine transporters. AAPS J. 2005, 7, E739–E751. [CrossRef]

56. Darke, S.; Kaye, S.; McKetin, R.; Duﬂou, J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev.

2009, 27, 253–262. [CrossRef] [PubMed]

57. Teixeira-Gomes, A.; Costa, V.M.; Feio-Azevedo, R.; de Lourdes Bastos, M.; Carvalho, F.; Capela, J.P. The neurotoxicity of

amphetamines during the adolescent period. Int. J. Dev. Neurosci. 2015, 41, 44–62. [CrossRef] [PubMed]

58. O’Brien, C.; Rose Childress, A.; Thomas Mclellan, A.; Ehrman, R. Classical Conditioning in Drug-Dependent Humans. Ann. N. Y.

Acad. Sci. 1992, 654, 400–415. [CrossRef]

59. Danaceau, J.P.; Deering, C.E.; Day, J.E.; Smeal, S.J.; Johnson-Davis, K.L.; Fleckenstein, A.E.; Wilkins, D.G. Persistence of tolerance

to methamphetamine-induced monoamine deﬁcits. Eur. J. Pharmacol. 2007, 559, 46–54. [CrossRef] [PubMed]

60. Carrico, A.; Johnson, M.; Morin, S.F.; Remien, R.; Riley, E.D.; Hecht, F.; Fuchs, D. Stimulant Use is Associated with Immune
Activation and Depleted Tryptophan Among HIV-Positive Persons on Anti-Retroviral Therapy. Brain Behav. Immun. 2008, 22,
1257–1262. [CrossRef] [PubMed]

61. Bradley, K.; Case, J.A.C.; Khan, O.; Ricart, T.; Hanna, A.; Alonso, C.; Gabbay, V. The role of the kynurenine pathway in suicidality

62.

in adolescent major depressive disorder. Psychiatry Res. 2015, 227, 206–212. [CrossRef]
Fleckenstein, A.E.; Volz, T.J.; Riddle, E.L.; Gibb, J.W.; Hanson, G.R. New Insights into the Mechanism of Action of Amphetamines.
Annu. Rev. Pharmacol. Toxicol. 2007, 47, 681–698. [CrossRef]

63. Halpin, L.E.; Collins, S.A.; Yamamoto, B.K. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life

Sci. 2014, 97, 37–44. [CrossRef]
Fiore, A.; Murray, P.J. Tryptophan and indole metabolism in immune regulation. Curr. Opin. Immunol. 2021, 70, 7–14. [CrossRef]
64.
65. Davidson, M.; Rashidi, N.; Nurgali, K.; Apostolopoulos, V. The Role of Tryptophan Metabolites in Neuropsychiatric Disorders.

Int. J. Mol. Sci. 2022, 23, 9968. [CrossRef]

66. Bryleva, E.; Brundin, L. Kynurenine Pathway Metabolites and Suicidality. Neuropharmacology 2017, 112, 324–330. [CrossRef]
67. Engin, A.; Engin, A. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease; Humana Press: Totowa, NJ,

USA, 2015. [CrossRef]

68. Petit, A.; Karila, L.; Chalmin, F.; Lejoyeux, M. Methamphetamine addiction: A review of the literature. J. Addict. Res. Ther. S 2012,

1, 1–6. [CrossRef]

Int. J. Mol. Sci. 2023, 24, 2737

15 of 17

Savitz, J. The kynurenine pathway: A ﬁnger in every pie. Mol. Psychiatry 2020, 25, 131–147. [CrossRef] [PubMed]

69.
70. Platten, M.; Nollen, E.A.; Röhrig, U.F.; Fallarino, F.; Opitz, C.A. Tryptophan metabolism as a common therapeutic target in cancer,

neurodegeneration and beyond. Nat. Rev. Drug Discov. 2019, 18, 379–401. [CrossRef]

71. Cheong, J.E.; Ekkati, A.; Sun, L. A patent review of IDO1 inhibitors for cancer. Expert Opin. Ther. Pat. 2018, 28, 317–330. [CrossRef]

[PubMed]

72. Andersen, M.H. The targeting of tumor-associated macrophages by vaccination. Cell Stress 2019, 3, 139. [CrossRef] [PubMed]
73. Borish, L.C.; Steinke, J.W. 2. Cytokines and chemokines. J. Allergy Clin. Immunol. 2003, 111, S460–S475. [CrossRef] [PubMed]
74. Van der Meide, P.H.; Schellekens, H. Cytokines and the immune response. Biotherapy 1996, 8, 243–249. [CrossRef]
75. Li, Y.; Hu, N.; Yang, D.; Oxenkrug, G.; Yang, Q. Regulating the balance between the kynurenine and serotonin pathways of

tryptophan metabolism. FEBS J. 2017, 284, 948–966. [CrossRef]

76. Maddison, D.C.; Giorgini, F. The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 2015, 40, 134–141.

[CrossRef] [PubMed]

77. Boyen, G.; Steinkamp, M.; Reinshagen, M.; Schäfer, K.-H.; Adler, G.; Kirsch, J. Proinﬂammatory cytokines increase glial ﬁbrillary

acidic protein expression in enteric glia. Gut 2004, 53, 222–228. [CrossRef]

78. Gibney, G.T.; Hamid, O.; Lutzky, J.; Olszanski, A.J.; Mitchell, T.C.; Gajewski, T.F.; Chmielowski, B.; Hanks, B.A.; Zhao, Y.; Newton,
R.C. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J.
Immunother. Cancer 2019, 7, 80. [CrossRef] [PubMed]

79. Gomes, B.; Driessens, G.; Bartlett, D.; Cai, D.; Cauwenberghs, S.; Crosignani, S.; Dalvie, D.; Denies, S.; Dillon, C.P.; Fantin, V.R.
Characterization of the selective indoleamine 2, 3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports
IDO1 as a critical resistance mechanism to PD-(L) 1 blockade therapy. Mol. Cancer Ther. 2018, 17, 2530–2542. [CrossRef]

80. Hassanzadeganroudsari, M.; Soltani, M.; Heydarinasab, A.; Nakhjiri, A.T.; Hossain, M.D.K.; Khiyavi, A.A. Mathematical
modeling and simulation of molecular mass transfer across blood brain barrier in brain capillary. J. Mol. Liq. 2020, 310, 113254.
[CrossRef]

81. Gobaille, S.; Kemmel, V.; Brumaru, D.; Dugave, C.; Aunis, D.; Maitre, M. Xanthurenic acid distribution, transport, accumulation

and release in the rat brain. J. Neurochem. 2008, 105, 982–993. [CrossRef] [PubMed]

82. Dostal, C.; Carson Sulzer, M.; Kelley, K.W.; Freund, G.; McCusker, R.H. Glial and tissue-speciﬁc regulation of Kynurenine Pathway

dioxygenases by acute stress of mice. Neurobiol. Stress 2017, 7, 1–15. [CrossRef]

83. Koshiguchi, M.; Komazaki, H.; Hirai, S.; Egashira, Y. Ferulic acid suppresses expression of tryptophan metabolic key enzyme
indoleamine 2, 3-dioxygenase via NFκB and p38 MAPK in lipopolysaccharide-stimulated microglial cells. Biosci. Biotechnol.
Biochem. 2017, 81, 966–971. [CrossRef] [PubMed]

84. Badawy, A.A.B. Tryptophan metabolism in alcoholism. Nutr. Res. Rev. 2002, 15, 123–152. [CrossRef]
85. Merz, F. United Nations Ofﬁce on Drugs and Crime: World Drug Report 2017. 2017. SIRIUS-Z. Strateg. Anal. 2018, 2, 85–86.

[CrossRef]

86. Azmi, A.; Jai, J.; Zamanhuri, N.; Yahya, A. Precious metals recovery from electroplating wastewater: A review. In IOP Conference

Series: Materials Science and Engineering; IOP Publishing: Bristol, UK, 2018; p. 012024.

87. Vrajová, M.; Šlamberová, R.; Hoschl, C.; Ovsepian, S.V. Methamphetamine and sleep impairments: Neurobehavioral correlates

and molecular mechanisms. Sleep 2021, 44, zsab001. [CrossRef] [PubMed]

88. Rawson, R.A.; Gonzales, R.; Marinelli-Casey, P.; Ang, A. Methamphetamine dependence: A closer look at treatment response and
clinical characteristics associated with route of administration in outpatient treatment. Am. J. Addict. 2007, 16, 291–299. [CrossRef]
89. McKetin, R.; Voce, A.; Burns, R.; Shanahan, M. Health-related quality of life among people who use methamphetamine. Drug

Alcohol Rev. 2019, 38, 503–509. [CrossRef] [PubMed]

90. McKetin, R.; Lubman, D.I.; Lee, N.M.; Ross, J.E.; Slade, T.N. Major depression among methamphetamine users entering drug

treatment programs. Med. J. Aust. 2011, 195, S51–S55. [CrossRef]

91. Hoffman, W.F.; Jacobs, M.B.; Dennis, L.E.; McCready, H.D.; Hickok, A.W.; Smith, S.B.; Kohno, M. Psychopathy and corticostriatal

connectivity: The link to criminal behavior in methamphetamine dependence. Front. Psychiatry 2020, 11, 90. [CrossRef]

92. Newton, T.F.; De La Garza, R.; Kalechstein, A.D.; Tziortzis, D.; Jacobsen, C.A. Theories of addiction: Methamphetamine users’

93.

explanations for continuing drug use and relapse. Am. J. Addict. 2009, 18, 294–300. [CrossRef] [PubMed]
Filip, M.; Bader, M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.
Pharmacol. Rep. 2009, 61, 761–777. [CrossRef]

94. Haughey, H.; Fleckenstein, A.E.; Hanson, G.R.; Haughey, H.M.; Fleckenstein, A.E.; Hanson, G.R. Differential regional effects of

methampetamine on the activities of tryptophan and tyrosine hydroxylase. J. Neurochem. 1999, 72, 661–668. [CrossRef]

95. Kobayashi, H.; Ujike, H.; Iwata, N.; Inada, T.; Yamada, M.; Sekine, Y.; Uchimura, N.; Iyo, M.; Ozaki, N.; Itokawa, M.; et al. Associa-
tion Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis.
Curr. Neuropharmacol. 2011, 9, 176–182. [CrossRef]
Sitte, H.; Freissmuth, M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol. Sci.
2015, 36, 41–50. [CrossRef]

96.

97. Hasler, B.; Smith, L.J.; Cousins, J.; Bootzin, R. Circadian Rhythms, Sleep, and Substance Abuse. Sleep Med. Rev. 2012, 16, 67–81.

[CrossRef]

Int. J. Mol. Sci. 2023, 24, 2737

16 of 17

98. Andersen, M.; Perez Diaz, M.; Murnane, K.; Howell, L.L. Effects of methamphetamine self-administration on actigraphy-based

sleep parameters in rhesus monkeys. Psychopharmacology 2013, 227, 101–107. [CrossRef]

99. Kuwano, N.; Kato, T.; Setoyama, D.; Sato-Kasai, M.; Shimokawa, N.; Hayakawa, K.; Ohgidani, M.; Sagata, N.; Kubo, H.;
Kishimoto, J.; et al. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for ﬁrst-episode drug-naïve
patients with major depressive disorder: An exploratory pilot case-control study. J. Affect. Disord. 2018, 231, 74–82. [CrossRef]

100. Stone, T.; Stoy, N.; Gail Darlington, L. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol.

Sci. 2013, 34, 136–143. [CrossRef]

101. Rassoulpour, A.; Wu, H.Q.; Poeggeler, B.; Schwarcz, R. Systemic d-amphetamine administration causes a reduction of kynurenic

acid levels in rat brain. Brain Res. 1998, 802, 111–118. [CrossRef] [PubMed]

102. Carlborg, A.; Jokinen, J.; Jönsson, E.; Erhardt, S.; Nordstrom, P. CSF kynurenic acid and suicide risk in schizophrenia spectrum

psychosis. Psychiatry Res. 2013, 205, 165–167. [CrossRef] [PubMed]

103. Shimosato, K.; Nagao, N.; Watanabe, S.; Kitayama, S. Suppressive effects of trihexyphenidyl on methamphetamine-induced DA

release as measured by in vivo microdialysis. Synapse 2003, 49, 47–54. [CrossRef] [PubMed]

104. Scoﬁeld, M. Similitude in Methamphetamine-Induced Neuroadaptations Across Susceptibility and Chronic Drug Exposure

Paradigms. Biol. Psychiatry 2017, 81, e83–e84. [CrossRef]

105. Haruki, H.; Hovius, R.; Grønlund Pedersen, M.; Johnsson, K. Tetrahydrobiopterin Biosynthesis as a Potential Target of the

Kynurenine Pathway Metabolite Xanthurenic Acid. J. Biol. Chem. 2016, 291, 652–657. [CrossRef]

106. Stone, T. Kynurenines in the CNS: From endogenous obscurity to therapeutic importance. Prog. Neurobiol. 2001, 64, 185–218.
107. Fazio, F.; Lionetto, L.; Curto, M.; Iacovelli, L.; Copeland, C.S.; Neale, S.A.; Bruno, V.; Battaglia, G.; Salt, T.; Nicoletti, F. Cinnabarinic
acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology
2017, 112, 365–372. [CrossRef] [PubMed]

108. Stone, T. Inhibitors of the Kynurenine Pathway. Eur. J. Med. Chem. 2000, 35, 179–186. [CrossRef] [PubMed]
109. Ribeiro, C.; Grando, V.; Dutra Filho, C.S.; Wannmacher, C.; Wajner, M. Evidence that quinolinic acid severely impairs energy
metabolism through activation of NMDA receptors in striatum from developing rats. J. Neurochem. 2006, 99, 1531–1542. [CrossRef]
[PubMed]

110. Guillemin, G. Quinolinic acid: Neurotoxicity. FEBS J. 2012, 279, 1355. [CrossRef]
111. Erhardt, S.; Lim, C.; Linderholm, K.; Janelidze, S.; Lindqvist, D.; Samuelsson, M.; Lundberg, K.; Postolache, T.; Träskman-Bendz,
L.; Guillemin, G.; et al. Connecting Inﬂammation with Glutamate Agonism in Suicidality. Neuropsychopharmacology 2012, 38,
743–752. [CrossRef]

112. Bay-Richter, C.; Linderholm, K.; Lim, C.; Samuelsson, M.; Träskman-Bendz, L.; Guillemin, G.; Erhardt, S.; Brundin, L. A role for
inﬂammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain
Behav. Immun. 2015, 43, 110–117. [CrossRef]

113. Van Heeringen, K.; Bijttebier, S.; Desmyter, S.; Vervaet, M.; Baeken, C. Is there a neuroanatomical basis of the vulnerability to
suicidal behavior? A coordinate-based meta-analysis of structural and functional MRI studies. Front. Hum. Neurosci. 2014, 8, 824.
[CrossRef]

114. Zarate, C.; Brutsche, N.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.; Liberty, V.;
Luckenbaugh, D. Replication of Ketamine’s Antidepressant Efﬁcacy in Bipolar Depression: A Randomized Controlled Add-On
Trial. Biol. Psychiatry 2012, 71, 939–946. [CrossRef] [PubMed]

115. Wang, B.; Chen, T.; Wang, J.; Jia, Y.; Ren, H.; Wu, F.; Hu, M.; Chen, Y. Methamphetamine modulates the production of interleukin-6
and tumor necrosis factor-alpha via the cAMP/PKA/CREB signaling pathway in lipopolysaccharide-activated microglia. Int.
Immunopharmacol. 2018, 56, 168–178. [CrossRef]

116. Grant, R.; Coggan, S.; Smythe, G. The Physiological Action of Picolinic Acid in the Human Brain. Int. J. Tryptophan Res. 2009, 2,

71–79. [CrossRef]

117. Davidson, J.; Abraham, K.; Connor, K.; McLeod, M.N. Effectiveness of Chromium in atypical depression: A placebo-controlled

trial. Biol. Psychiatry 2003, 53, 261–264. [CrossRef] [PubMed]

118. Rex, A.; Schickert, R.; Fink, H. Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.

Pharmacol. Biochem. Behav. 2004, 77, 303–307. [CrossRef] [PubMed]

119. Oka, S.-I.; Hsu, C.-P.; Sadoshima, J. Regulation of Cell Survival and Death by Pyridine Nucleotides. Circ. Res. 2012, 111, 611–627.

[CrossRef] [PubMed]

120. Salim, S. Oxidative Stress and Psychological Disorders. Curr. Neuropharmacol. 2014, 12, 140–147. [CrossRef] [PubMed]
121. Gawryluk, J.; Wang, J.-F.; Andreazza, A.C.; Shao, L.; Young, L.T. Decreased levels of glutathione, the major brain antioxidant, in
post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011, 14, 123–130. [CrossRef]
122. Lee, S.-Y.; Lee, S.-J.; Han, C.; A Patkar, A.; S Masand, P.; Pae, C.-U. Oxidative/nitrosative stress and antidepressants: Targets for

novel antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46, 224–235. [CrossRef] [PubMed]

123. Badawy, A.A.-B. Tryptophan metabolism: A versatile area providing multiple targets for pharmacological intervention. Egypt. J.

Basic Clin. Pharmacol. 2019, 9. [CrossRef] [PubMed]

124. Saberi, B. Alcoholism and Serotonin. Psychopharmacology 2019, 171, 340–348.
125. Kelley, K.W.; Dantzer, R. Alcoholism and inﬂammation: Neuroimmunology of behavioral and mood disorders. Brain Behav.

Immun. 2011, 25, S13–S20. [CrossRef]

Int. J. Mol. Sci. 2023, 24, 2737

17 of 17

126. Degenhardt, L.; Baxter, A.J.; Lee, Y.Y.; Hall, W.; Sara, G.E.; Johns, N.; Flaxman, A.; Whiteford, H.A.; Vos, T. The global epidemiology
and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drug Alcohol Depend. 2014,
137, 36–47. [CrossRef]

127. Araos, P.; Vergara-Moragues, E.; González-Saiz, F.; Pedraz, M.; García-Marchena, N.; Romero-Sanchiz, P.; Ruiz, J.J.; Campos-
Cloute, R.; Serrano, A.; Pavón, F.J. Differences in the rates of drug polyconsumption and psychiatric comorbidity among patients
with cocaine use disorders according to the mental health service. J. Psychoact. Drugs 2017, 49, 306–315. [CrossRef] [PubMed]

128. Shorter, D.; Domingo, C.B.; Kosten, T.R. Emerging drugs for the treatment of cocaine use disorder: A review of neurobiological

targets and pharmacotherapy. Expert Opin. Emerg. Drugs 2015, 20, 15–29. [CrossRef]

129. Myint, A.M.; Kim, Y.K. Cytokine–serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med.

Hypotheses 2003, 61, 519–525. [CrossRef] [PubMed]

130. Justinova, Z.; Mascia, P.; Wu, H.-Q.; Secci, M.E.; Redhi, G.H.; Panlilio, L.V.; Scherma, M.; Barnes, C.; Parashos, A.; Zara, T.
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat. Neurosci.
2013, 16, 1652–1661. [CrossRef]

131. Vengeliene, V.; Cannella, N.; Takahashi, T.; Spanagel, R. Metabolic shift of the kynurenine pathway impairs alcohol and cocaine

seeking and relapse. Psychopharmacology 2016, 233, 3449–3459. [CrossRef]

132. Wrona, M.Z.; Dryhurst, G. A putative metabolite of serotonin, tryptamine-4, 5-dione, is an irreversible inhibitor of tryptophan
hydroxylase: Possible relevance to the serotonergic neurotoxicity of methamphetamine. Chem. Res. Toxicol. 2001, 14, 1184–1192.
[CrossRef]

133. Zheng, T.; Liu, L.; Shi, J.; Yu, X.; Xiao, W.; Sun, R.; Zhou, Y.; Aa, J.; Wang, G. The metabolic impact of methamphetamine on the
systemic metabolism of rats and potential markers of methamphetamine abuse. Mol. BioSyst. 2014, 10, 1968–1977. [CrossRef]
[PubMed]

134. Jenny, M.; Schröcksnadel, S.; Überall, F.; Fuchs, D. The potential role of cannabinoids in modulating serotonergic signaling by

their inﬂuence on tryptophan metabolism. Pharmaceuticals 2010, 3, 2647–2660. [CrossRef]

135. McDew-White, M.; Lee, E.; Alvarez, X.; Sestak, K.; Ling, B.J.; Byrareddy, S.N.; Okeoma, C.M.; Mohan, M. Cannabinoid control of
gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-
1 pathway and salivary microbiome. EBioMedicine 2022, 75, 103769. [CrossRef]

136. Ishak, N.; Ahmad, A.H.; Noor, S.A.M.; Ahmad, A. Detection of heroin metabolites at different developmental stages of Lucilia
cuprina (Diptera: Calliphoridae) reared in heroin-treated meat: A preliminary analysis. Egypt. J. Forensic Sci. 2019, 9, 65.
[CrossRef]

137. Gaynor, C.M.; Handley, S.L. Effects of nicotine on head-shakes and tryptophan metabolites. Psychopharmacology 2001, 153, 327–333.

[CrossRef]

138. Fang, C.; Hayashi, S.; Du, X.; Cai, X.; Deng, B.; Zheng, H.; Ishido, S.; Tsutsui, H.; Sheng, J. Caffeine protects against stress-induced
murine depression through activation of PPARγC1α-mediated restoration of the kynurenine pathway in the skeletal muscle. Sci.
Rep. 2021, 11, 7287. [CrossRef]

139. Varma, S.D.; Hegde, K.R. Kynurenine-induced photo oxidative damage to lens in vitro: Protective effect of caffeine. Mol. Cell.

Biochem. 2010, 340, 49–54. [CrossRef]

140. Giménez-Gómez, P.; Ballestín, R.; de Biedma-Elduayen, L.G.; Vidal, R.; Ferrer-Pérez, C.; Reguilón, M.D.; O’Shea, E.; Miñarro, J.;
Colado, M.I.; Rodríguez-Arias, M. Decreased kynurenine pathway potentiate resilience to social defeat effect on cocaine reward.
Neuropharmacology 2021, 197, 108753. [CrossRef] [PubMed]

141. Fonseca, F.; Mestre-Pintó, J.-I.; Gómez-Gómez, À.; Martinez-Sanvisens, D.; Rodríguez-Minguela, R.; Papaseit, E.; Pérez-Mañá, C.;
Langohr, K.; Valverde, O.; Pozo, Ó.J. The tryptophan system in cocaine-induced depression. J. Clin. Med. 2020, 9, 4103. [CrossRef]
[PubMed]

142. Hossain, M.K.; Davidson, M.; Kypreos, E.; Feehan, J.; Muir, J.A.; Nurgali, K.; Apostolopoulos, V. Immunotherapies for the

Treatment of Drug Addiction. Vaccines 2022, 10, 1778. [CrossRef]

143. Kamal Hossain, M.; Davidson, M.; Feehan, J.; Deraos, G.; Nurgali, K.; Matsoukas, J.; Apostolopoulos, V. Development and

characterization of a novel conjugated methamphetamine vaccine. Vaccine 2022, 40, 5882–5891. [CrossRef] [PubMed]

144. Hossain, M.K.; Hassanzadeganroudsari, M.; Kypreos, E.; Feehan, J.; Apostolopoulos, V. Immune to addiction: How immunother-

apies can be used to combat methamphetamine addiction. Expert Rev. Vaccines 2021, 20, 707–715. [CrossRef]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
